Portola’s blood thinner antidote turned away by FDA
Portola has been dealt a blow after its anticoagulation reversal drug AndexXa was rejected by the US Food and Drug Administration.
Read More
Tag: antidote
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
